Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet
- Status
- UnknownResults none
- Who it enrolls
- age 18 Years to 65 Years; healthy volunteers accepted; excludes diabetes; BMI ≥32 required; conditions: Obesity
- Interventions
- Liraglutide; Exercise
- Conditions
- Obesity
- Phase and size
- Phase 4 · 215 participants
- Dates
- Start 2016-09
Primary completion 2019-11 - Sponsor
- Signe Torekov (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Body weight change (kg)Change from baseline to end-of-treatment (52 weeks)
Published results in the collection
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both CombinedRandomized trial · 2021 · Study tier 2 · Different population · Benefit · Partly industry funded
- Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trialRandomized trial · 2026 · Study tier 3 · Different population · Benefit · Partly industry funded · Unreviewed automatic assessment
- Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trialRandomized trial · 2023 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
02Eligibility
Who can take part
Inclusion Criteria: * BMI \> 32 and \< 43 (kg/m2) * Age \>18 and \<65 years * Safe contraceptive method Exclusion Criteria: * Patients diagnosed with known serious chronic illness including type 1 or 2 diabetes (or a randomly measured fasting plasma glucose \> 7 mmol/l) * Angina pectoris, coronary heart disease, congestive heart failure (NYHA III-IV) * Severe renal impairment (creatinine clearance (GFR) \<30 mL/min) * Severe hepatic impairment * Inflammatory bowel disease * Gastroparesis * Cancer * Chronic obstructive lung disease * Psychiatric disease, a history of major depressive or other severe psychiatric disorders * The use of medications that cause clinically significant weight gain or loss * Previous bariatric surgery * A history of idiopathic acute pancreatitis * A family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma * Osteoarthritis which is judged to be too severe to manage the exercise programme. As intended per study design the intervention will include a 5% weight loss prior to randomization, thus it is expected that possible participants with mild form of osteoarthritis will be able to manage exercise prescriptions. * Pregnancy, expecting pregnancy or breast feeding. If a study participant is in doubt whether she could be pregnant, a urine pregnancy test is performed. Females of childbearing potential who are not using adequate contraceptive methods (as required by local law or practice). Adequate contraception must be used throughout the study period and at least 65 hours after discontinuation of trial medication (65 hours corresponds to 5 times the half-life of Saxenda). Allergy to any of the ingredients/excipients. * Allergy to any of the ingredients/excipients of the study medication: liraglutide, disodium phosphate dihydrate, propylene glycol, phenol, hydrochloric acid, sodium hydroxide. * Regular exercise training at high intensity (e.g. spinning) \>2 hours per week.
03Change log
Registry changes
No changes recorded since the trial was added.